Resurgence of vitamin D: Old wine in new bottle

Journal of Clinical Orthopaedics and Trauma

Volumn 6, Issue 3, 2015, Pages 173-183

  Vaishya, Raju ^a   Vijay, Vipul ^a   Agarwal, Amit Kumar ^a   Jahangir, Jabed ^a  

^a INDRAPRASTHA APOLLO HOSPITAL   (India)

Author keywords

Extraskeletal; Metabolism; Osteomalacia; Rickets; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ANTICONVULSIVE AGENT; CALCITRIOL; CARBAMAZEPINE; CELL SURFACE RECEPTOR; COLECALCIFEROL; ERGOCALCIFEROL; MELANIN; MEMBRANE ASSOCIATED RAPID RESPONSE STEROID BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; SUNSCREEN; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

BIOLOGICAL ACTIVITY; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; FAT MALABSORPTION; GROWTH PLATE; HUMAN; HYPERTENSION; INDIA; INFLAMMATORY BOWEL DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; LIVER DYSFUNCTION; LONG TERM CARE; MALABSORPTION; MULTIPLE SCLEROSIS; NUTRITIONAL REQUIREMENT; OBESITY; OSSIFICATION; OSTEOARTHRITIS; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOMALACIA; PERIODONTAL DISEASE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SMALL INTESTINE ABSORPTION; SUN EXPOSURE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; ULTRAVIOLET B RADIATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D INTOXICATION; VITAMIN D METABOLISM; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

EID: 84937515051     PISSN: 09765662     EISSN: 22133445     Source Type: Journal    
DOI: 10.1016/j.jcot.2015.02.002     Document Type: Review

References (157)

1. McCollum E.V., Simmonds N., Becker J.E., Shiply P.G. Studies on experimental rickets. An experimental demonstration the existence of a vitamin which promotes calcium deposition. J Biol Chem 1922, 53:293-312.
2. Wolf G. The discovery of vitamin D: the contribution of Adolf Windaus. J Nutr 2004, 134:1299-1302.
3. Holick M.F. High prevalence of VD inadequacy and implications for health. Mayo Clin Proc 2006, 81:353-375.
4. Holick M.F. The use and interpretation of assays for VD and its metabolites. J Nutr 1990, 120(suppl 11):1464-1469.
5. Vieth R. Why 'vitamin D' is not a hormone, and not a synonym for 1,25dihydroxy-vitamin D, its analogs or deltanoids. J Steroid Biochem Mol Biol 2004, 89-90:571-573.
6. Holick M.F. McCollum Award Lecture, 1994: vitamin D-new horizons for the 21st century. Am J Clin Nutr 1994, 60:619-630.
7. MacLaughlin J.A., Anderson R.R., Holick M.F. Spectral character of sunlight modulates photosynthesis of previtamin D3 and its photoisomers in human skin. Science 1982, 216:1001-1003.
8. Bjelakovic G., Gluud L.L., Nikolova D., Whitfield K. VD supplementation for prevention of mortality in adults. Cochrane Database Syst Rrev 2014, 1:CD007470.
9. Cooke N.E., Haddad J.G. VD binding protein (Gc-globulin). Endocr Rev 1989, 10:294-307.
10. Brown A.J., Dusso A., Slatopolsky E., Vitamin D. Am J Physiol Renal Physiol 1999, 277:157-175.
11. Boyan B.D., Dean D.D., Sylvia V.L., Schwartz Z. Nongenomic regulation of extracellular matrix events by VD metabolites. J Cell Biochem 1994, 56:331-339.
12. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001, 142:5050-5055.
13. Dietary reference intakes tables [Health Canada 2005].
14. Calvo M.S., Whiting S.J., Barton C.N. VD intake: a global perspective of current status. J Nutr 2005, 135:310-316.
15. Norman A.W. From VD to hormone D: fundamental of the VD endocrine system essential for good health. Am J Clin Nutr 2008, 88:491s-499.
16. Holick M.F. VDD. N Engl J Med 2007, 357:266-281.
17. Schoenmakers I., Goldberg G.R., Prentice A. Abundant sunshine and VDD. Br J Nutr 2008, 99:1171-1173.
18. DRI, Dietary Reference Intakes: For Calcium, Phosphorus, Magnesium, Vitamin D, and fluoride 1997, 250. National Academy Press, Washington, D.C.
19. Wang T., Bengtsson G., Kärnefelt I., et al. Provitamins and vitamins D2 and D3 in Cladina spp. over a latitudinal gradient: possible correlation with UV levels. J Photochem Photobiol B, Biol September 2001, 62:118-122.
20. Holick M.F. The VD epidemic and its health consequences. J Nutr 2005, 135. 2739S-48S.
21. Takeuchi A., Okano T., Sayamoto M., et al. Tissue distribution of 7-dehydrocholesterol, vitamin D3 and 25-hydroxyvitamin D3 in several species of fishes. J Nutr Sci Vitaminol 1986, 32:13-22.
22. Wolpowitz D., Gilchrest B.A. The VD questions: how much do you need and how should you get it?. J Am Acad Dermatol 2006, 54:301-317.
23. Adams J.S., Clemens T.L., Parrish J.A., Holick M.F. Vitamin-D synthesis and metabolism after ultraviolet irradiation of normal and vitamin-D deficient subjects. N Engl J Med 1982, 306:722-725.
24. Reichel H., Koeffler H.P., Norman A.W. The role of the VD endocrine system in health and disease. N Engl J Med 1989, 320:980-991.
25. Hollis B.W., Wagner C.L. Assessment of dietary VD requirements during pregnancy and lactation. Am J Clin Nutr 2004, 79:717-726.
26. Holick M.F., Siris E.S., Binkley N., et al. Prevalence of VD inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005, 90:3215-3224.
27. Lips P., Hosking D., Lippuner K., et al. The prevalence of VD inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med 2006, 260:245-254.
28. Thomas K.K., Lloyd-Jones D.M., Thadhani R.I., et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998, 338:777-783.
29. Dawson-Hughes B., Heaney R.P., Holick M.F., Lips P., Meunier P.J., Vieth R. Estimates of optimal VD status. Osteoporos Int 2005, 16:713-716.
30. Bell N.H. VD metabolism, aging, and bone loss. J Clin Endocrinol Metab 1995, 80:1051.
31. Need A.G., Morris H.A., Horowitz M., Nordin C. Effects of skin thickness, age, body fat, and sunlight on serum 25-hydroxyvitamin D. Am J Clin Nutr 1993, 58:882-885.
32. Clemens T.L., Henderson S.L., Adams J.S., Holick M.F. Increased skin pigment reduces the capacity of skin to synthesis vitamin D3. Lancet 1982, 1:74-76.
33. Webb A.R., Kline L., Holick M.F. Influence of season and latitude on the cutaneous synthesis of vitaminD3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988, 67:373-378.
34. Lu Z., Chen T.C., Kline L., et al. Photosynthesis of previtamin D3 in cities around the world. Symposium proceedings, October 13-15:1991 1992, 48-51. Walter De Gruyter, Berlin. M.F. Holick, A. Kligman (Eds.).
35. Matsuoka L.Y., Ide L., Wortsman J., MacLaughlin J., Holick M.F. Sunscreens suppress cutaneous vitamin D3 synthesis. J Clin Endocrinol Metab 1987, 64:1165-1168.
36. Lo C.W., Paris P.W., Clemens T.L., Nolan J., Holick M.F. VD absorption in healthy subjects and in patients with intestinal malabsorption syndromes. Am J Clin Nutr 1985, 42:644-649.
37. Pack A.M., Morrell M.J. Epilepsy and bone health in adults. Epilepsy Behav 2004, 5(suppl 2):S24-S29.
38. Andress D.L., Ozuna J., Tirschwell D., et al. Antiepileptic drug induced bone loss in young male patients who have seizures. Arch Neurol 2002, 59:781-786.
39. Burt R., Freston J.W., Tolman K.G. The influence of phenobarbital on biotransformation of 25-hydroxycholecalciferol. J Clin Pharmacol 1976, 16:393-398.
40. Shah S.C., Sharma R.K., Chitle A.R. Rifampicin induced osteomalacia. Tubercle 1981, 62:207-209.
41. Karaaslan Y., Haznedaroglu S., Ozturk M. Osteomalacia associated with carbamazepine/valproate. Ann Pharmacother 2000, 34:264-265.
42. Dusso A.S., Sato T., Arcidiacono M.V., et al. Pathogenic mechanisms for parathyroid hyperplasia. Kidney Int Suppl 2006, 102:S8-S11.
43. Correa P., Segersten U., Hellman P., Akerstrom G., Westin G. Increased 25-hydroxyvitamin D3 1α-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase expression in parathyroid tumors - new prospects for treatment of hyperparathyroidism with vitamin D. J Clin Endocrinol Metab 2002, 87:5826-5829.
44. Putz-Bankuti C., Pilz S., Stojakovic T., et al. Association of 25-hydroxyVDlevels with liver dysfunction and mortality in chronic liver disease. Liver Int 2012, 32:845-851.
45. Arteh J., Narra S., Nair S. Prevalence of VDD in chronic liver disease. Dig Dis Sci 2010, 55:2624-2628.
46. Malham M., Jorgensen S.P., Ott P., et al. VDD in cirrhosis relates to liver dysfunction rather than aetiology. World J Gastroenterol 2011, 17:922-925.
47. Miroliaee A., Nasiri-Toosi M., Khalilzadeh O., Esteghamati A., Abdollahi A., Mazloumi M. Disturbances of parathyroid hormone-VDaxis in non-cholestatic chronic liver disease: a cross-sectional study. Hepatol Int 2010, 4:634-640.
48. Fisher L., Fisher A. VDand parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol 2007, 5:513-520.
49. Liel Y., Ulmer E., Shary J., Hollis B.W., Bell N.H. Low circulating VD in obesity. Calcif Tissue Int 1988, 43:199-201.
50. Compston J.E., Vedi S., Ledger J.E., Webb A., Gazet J.C., Pilkington T.R.E. VD status and bone histomorphometry in gross obesity. Am J Clin Nutr 1981, 34:2359-2363.
51. Hey H., Stockholm K.H., Lund B.J., Sorensen O.H. VDD in obese patients and changes in circulating VD metabolites following jejunoileal bypass. Int J Obes 1982, 6:473-479.
52. Hyldstrup L., Andersen T., McNair P., Breum L., Transbol I. Bone metabolism in obesity: changes related to severe overweight and dietary weight reduction. Acta Endocrinol 1993, 129:393-398.
53. MacLaughlin J., Holick M.F. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 1985, 76:1536-1538.
54. Wortsman J., Matsuoka L.Y., Chen T.C., Lu Z., Holick M.F. Decreased bioavailability of VD in obesity. Am J Clin Nutr 2000, 72:690-693.
55. Van Schoor N.M., Lips P. Worldwide VD status. Best Pract Res Clin Endocrinol.Metab 2011, 25:671-680.
56. Mithal A., Wahl D.A., Bonjour J.P., et al. Global VD status and determinants of hypovitaminosis D. Osteoporos Int 2009, 20:1807-1820.
57. Van der Meer I.M., Middelkoop B.J., Boeke A.J., Lips P. Prevalence of VDD among Turkish, Moroccan, Indian and sub-Sahara African populations in Europe and their countries of origin: an overview. Osteoporos Int 2011, 22:1009-1021.
58. Sullivan S.S., Rosen C.J., Halteman W.A., Chen T.C., Holick M.F. Adolescent girls in Maine at risk for VD insufficiency. J Am Diet Assoc 2005, 105:971-974.
59. Gordon C.M., DePeter K.C., Feldman H.A., Grace E., Emans S.J. Prevalence of VDD among healthy adolescents. Arch Pediatr Adolesc Med 2004, 158:531-537.
60. Lips P. VDD and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001, 22:477-501.
61. Bakhtiyarova S., Lesnyak O., Kyznesova N., Blankenstein M.A., Lips P. VD status among patients with hip fracture and elderly control subjects in Yekaterinburg, Russia. Osteoporos Int 2006, 17:441-446.
62. McKenna M.J. Differences in VD status between countries in young adults and the elderly. Am J Med 1992, 93:69-77.
63. Hypponen, Power Hypovitaminosis D in British adults at age 45y: nationwide cohort study on dietary and lifestyle predictors. Am J Clin Nutr 2007, 85:860-868.
64. Baidya A., Chowdhury S., Mukhopadhyay S., Ghosh S. Profile of VD in a cohort of physicians and diabetologists in Kolkata. Indian J Endocrinol.Metab 2012, 16:S416-S417.
65. Goswami R., Gupta N., Goswami D., Marwaha R.K., Tandon N., Kochupillai N. Prevalence and significance of low 25-hydroxy VD concentrations in healthy subjects in Delhi. Am J.Clin. Nutr 2000, 72:472-475.
66. Tandon N., Marwaha R.K., Kalra S., Gupta N., Dudha A., Kochupillai N. Bone mineral parameters in healthy young Indian adults with optimal VD availability. Natl Med J.India 2003, 16:298-302.
67. Marwaha R.K., Puri S., Tandon N., et al. Effects of sports training & nutrition on bone mineral density in young Indian healthy females. Indian J Med Res 2011, 134:307-313.
68. Multani S.K., Sarathi V., Shivane V., Bandgar T.R., Menon P.S., Shah N.S. Study of bone mineral density in resident doctors working at a teaching hospital. J Postgrad Med 2010, 56:65-70.
69. Beloyartseva M., Mithal A., Kaur P., et al. Widespread VDD among Indian health care professionals. Arch Osteoporos 2012, 7:187-192.
70. Holick M.F. Sunlight and VD for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004, 80(6,suppl l):1678S-1688S.
71. Holick M., Jenkins M. The UV Advantage 2003, iBooks, NewYork, NY.
72. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes Food and Nutrition Board Institute of Medicine Vitamin D. DietaryReference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride 1997, 250-287. National Academy Press, Washington, DC.
73. Malabanan A., Veronikis I.E., Holick M.F. Redefining VD insufficiency [letter]. Lancet 1998, 351:805-806.
74. Eriksen E.F., Glerup H. VDD and aging: implications for general health and osteoporosis. Biogerontology 2002, 3:73-77.
75. Glerup H., Mikkelsen K., Poulsen L., et al. Commonly recommended daily intake of VD is not sufficient if sunlight exposure is limited. J Intern Med 2000, 247:260-268.
76. Feskanich D., Willett W.C., Colditz G.A. Calcium, vitamin D, milk consumption, and hip fractures: a prospective study among postmenopausal women. Am J Clin Nutr 2003, 77:504-511.
77. Dawson-Hughes B., Harris S.S., Krall E.A., Dallal G.E. Effect of calcium and VD supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997, 337:670-676.
78. Lips P., Wiersinga A., van Ginkel F.C., et al. The effect of VD supplementation on VD status and parathyroid function in elderly subjects. J Clin Endocrinol Metab 1988, 67:644-650.
79. Grant A.M., Avenell A., Campbell M.K., et al. RECORD Trial Group. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised evaluation of calcium or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005, 365:1621-1628.
80. Chapuy M.C., Chapuy P., Thomas J.L., Hazard M.C., Meunier P.J. Biochemical effects of calcium and VD supplementation in elderly, institutionalized, vitamin D-deficient patients. Rev Rhum Engl Ed 1996, 63:135-140.
81. Chel V.G.M., Ooms M.E., Popp-Snijders C., et al. Ultraviolet irradiation corrects VDD and suppresses secondary hyperparathyroidism in the elderly. J Bone Miner Res 1998, 13:1238-1242.
82. Tangpricha V., Turner A., Spina C., Decastro S., Chen T.C., Holick M.F. Tanning is associated with optimal VD status (serum 25-hydroxy VD concentration) and higher bone mineral density. Am J Clin Nutr 2004, 80:1645-1649.
83. Chuck A., Todd J., Diffey B. Subliminal ultraviolet-B irradiation for the prevention of VDD in the elderly: a feasibility study. Photodermatol Photoimmunol Photomed 2001, 17:168-171.
84. Shao Q., Chen T.C., Holick M.F. Sun-tanning bed radiation increases VD synthesis in human skin in vivo. Biological Effects of Light 1992, 62-66. Walter De Gruyter, Berlin, Germany. M.F. Holick, A. Kligman (Eds.).
85. Holick M.F. VD requirements for humans of all ages: new increased requirements for women and men 50 years and older. Osteoporos Int 1998, 8(suppl 2):S24-S29.
86. Scientific Committee on Food. Opinion on the Tolerable Upper Intake Level of Vitamin D December 4, 2002, Available at:, Accessibility verified January 31, 2006. http://www.imace.org/nutrition/pdf/poster.pdf.
87. United States Food and Drug Administration Web site. Reference Daily Intakes, Recommended Dietary Allowances. Available at: . Accessibility verified February 13, 2006. http://www.fda.gov/fdac.
88. Tangpricha V., Koutkia P., Rieke S.M., Chen T.C., Perez A.A., Holick M.F. Fortification of orange juice with vitamin D: a novel approach to enhance VD nutritional health. Am J Clin Nutr 2003, 77:1478-1483.
89. Heaney R.P., Dowell M.S., Hale C.A., Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr. 2003, 22:142-146.
90. Vieth R. Why the optimal requirement for vitamin D3 is probably much higher than what is officially recommended for adults. J Steroid Biochem Mol Biol. 2004, 89-90:575-579.
91. Hollis B.W. Circulating 25-hydroxy VD levels indicative of VD sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005, 135:317-322.
92. Koutkia P., Lu Z., Chen T.C., Holick M.F. Treatment of VDD due to Crohn's disease with tanning bed ultraviolet B radiation. Gastroenterology 2001, 121:1485-1488.
93. Freedman D.M., Dosemeci M., McGlynn K. Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study. Occup Environ Med 2002, 59:257-262.
94. Heaney R.P., Davies K.M., Chen T.C., Holick M.F., Barger-Lux M.J. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003, 77:204-210. [published correction appears in.
95. Matuulla-Nolte B., Krause B., Schmidt-Gayk H. Serial UVB irradiation can influence secondary hyperparathyroidism in VDD. Biologic Effects of Light: Proceedings of a Symposium, Basel, Switzerland, November 1-3, 1998 1999, 121-123. Kluwer Academic Publishers, Boston, Mass. M.F. Holick, E.G. Jung (Eds.).
96. Holick M.F., Garabedian M. Vitamin D: photobiology, metabolism, mechanism of action, and clinical applications. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 2006, 129-137. American Society for Bone and Mineral Research, Washington, DC. 6th ed. M.J. Favus (Ed.).
97. Bouillon R. Vitamin D: from photosynthesis, metabolism, and action to clinical applications. Endocrinology 2001, 1009-1028. W.B. Saunders, Philadelphia. L.J. DeGroot, J.L. Jameson (Eds.).
98. Holick M.F. Resurrection of VDD and rickets. J Clin Invest 2006, 116:2062-2072.
99. Insel P.M., Turner E.R., Ross D. Discovering Nutrition 2006, Jones and Bartlett Publishers, Boston. 2nd ed.
100. Holick M.F. Vitamin D: a millenium perspective. J Cell Biochem 2003, 88:296-307.
101. DeLuca H. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004, 80(6, suppl l):1689S-1696S.
102. Stumpf W.E., Sar M., Reid F.A., Tanaka Y., DeLuca H.F. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979, 206:1188-1190.
103. Mawer E.B., Hayes M.E., Heys S.E., et al. Constitutive synthesis of 1,25-dihydroxyvitamin D3 by a human small cell lung cancer cell line. J Clin Endocrinol Metab 1994, 79:554-560.
104. Schwartz G.G., Whitlatch L.W., Chen T.C., Lokeshwar B.L., Holick M.F. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25- hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 1998, 7:391-395.
105. Cross H.S., Bareis P., Hofer H., et al. 25-Hydroxyvitamin D3-1α-hydroxlyase and VD receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 2001, 66:287-292.
106. Tangpricha V., Flanagan J.N., Whitlatch L.W., et al. 25-Hydroxyvitamin D-1α-hydroxylase in normal and malignant colon tissue. Lancet 2001, 357:1673-1674.
107. Holick M.F. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 2004, 79:362-371. [published correction appears in Am J Clin Nutr. 2004;79:890].
108. Chen T.C., Holick M.F. VD and prostate cancer prevention and treatment. Trends Endocrinol Metab 2003, 14:423-430.
109. Rachez C., Freedman L.P. Mechanisms of gene regulation by vitamin D3 receptor: a network of coactivator interactions. Gene 2000, 246:9-21.
110. Grant W.B., Holick M.F. Benefits and requirements of VD for optimal health: a review. Altern Med Rev 2005, 10:94-111.
111. Holick M.F. Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr Opin Endocrinol Diabetes 2002, 9:87-98.
112. Uitterlinden A.G., Fang Y., van Meurs J.B., van Leeuwen H., Pols H.A. VD receptor gene polymorphisms in relation to VD related disease states. J Steroid Biochem Mol Biol 2004, 89-90:187-193.
113. Slattery M.L., Neuhausen S.L., Hoffman M., et al. Dietary calcium, vitamin D, VDR genotypes and colorectal cancer. Int J Cancer 2004, 111:750-756. [published correction appears in Int J Cancer. 2004;111:983].
114. Pani M.A., Knapp M., Donner H., et al. VD receptor allele combinations influence genetic susceptibility to type 1 diabetes in Germans. Diabetes 2000, 49:504-507.
115. McDermott M.F., Ramachandran A., Ogunkolade B.W., et al. Allelic variation in the VD receptor influences susceptibility to IDDM in Indian Asians. Diabetologia 1997, 40:971-975.
116. Nagpal S., Na S., Rathnachalam R. Noncalcemic actions of VD receptor ligands. Endocr Rev 2005, 26:662-687.
117. Omdahl J.L., Morris H.A., May B.K. Hydroxylase enzymes of the VD pathway: expression, function, and regulation. Annu Rev Nutr 2002, 22:139-166.
118. Falkenstein E., Tillmann H.C., Christ M., Feuring M., Wehling M. Multiple actions of steroid hormones-a focus on rapid, nongenomic effects. Pharmacol Rev 2000, 52:513-556.
119. Norman A.W., Bishop J.E., Bula C.M., et al. Molecular tools for study of genomic and rapid signal transduction responses initiated by 1α,25(OH)2- vitamin D3. Steroids 2002, 67:457-466.
120. Chen T.C., Holick M.F., Lokeshwar B.L., Burnstein K.L., Schwartz G.G. Evaluation of VD analogs as therapeutic agents for prostate cancer. Recent Results Cancer Res 2003, 164:273-288.
121. Harris S.S. VDand type 1 diabetes [letter]. Am J Clin Nutr 2004, 79:889-890.
122. Holick M.F. Clinical efficacy of 1,25-dihydroxyvitamin D3 and its analogues in the treatment of psoriasis. Retinoids 1998, 14:12-17.
123. Holick M.F. Evolution and function of vitamin D. Recent Results Cancer Res 2003, 164:3-28.
124. Van den Bemd G.J., Chang G.T. VD and VD analogs in cancer treatment. Curr Drug Targets 2002, 3:85-94.
125. Abe J., Nakamura K., Takita Y., Nakano T., Irie H., Nishii Y. Prevention of immunological disorders in MRL/1 mice by a new synthetic analogue of vitamin D3: 22-oxa-1α,25-dihydroxyvitamin D3. J Nutr Sci Vitaminol (Tokyo) 1990, 36:21-31.
126. Dalhoff K., Dancey J., Astrup L., et al. A phase II study of the VD analogue seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 2003, 89:252-257.
127. Mantell D.J., Owens P.E., Bundred N.J., Mawer E.B., Canfield A.E. 1α,25-Dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo. Circ Res 2000, 87:214-220.
128. Ylikomi T., Laaksi I., Lou Y.R., et al. Antiproliferative action of vitamin D. Vitam Horm 2002, 64:357-406.
129. Sambrook P.N., Chen J.S., March L.M., et al. Serum parathyroid hormone predicts time to fall independent of VD status in a frail elderly population. J Clin Endocrinol Metab 2004, 89:1572-1576.
130. Krause R., Buhring M., Hopfenmuller W., Holick M.F., Sharma A.M. Ultraviolet B and blood pressure [letter]. Lancet 1998, 352:709-710.
131. Rostand S.G. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1997, 30(2,pt 1):150-156.
132. Zhao X.Y. Feldman D.The role of VD in prostate cancer. Steroids 2001, 66:293-300.
133. Apperly F.L. The relation of solar radiation to cancer mortality in North America. Cancer Res 1941, 1:191-195.
134. Grant W.B. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94:1867-1875.
135. John E.M., Schwartz G.G., Dreon D.M., Koo J. VDand breast cancer risk: the NHANES I epidemiologic follow-up study, 1971-1975 to 1992: National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 1999, 8:399-406.
136. Grant W.B. An ecologic study of the role of solar UV-B radiation in reducing the risk of cancer using cancer mortality data, dietary supply data and latitude for European countries. Biologic Effects of Light 2001: Proceedings of a Symposium, Boston, Massachusetts 2002, 267-276. Mass:Kluwer Academic Publishing, Boston. M.F. Holick (Ed.).
137. Li Y.C. VDregulation of the renin-angiotensin system. J Cell Biochem 2003, 88:327-331.
138. Hernan M.A., Olek M.J., Ascherio A. Geographic variation of MS incidence in two prospective studies of US women. Neurology 1999, 53:1711-1718.
139. Leibowitz U., Sharon D., Alter M. Geographical considerations in multiple sclerosis. Brain 1967, 90:871-886.
140. Ponsonby A.L., McMichael A., van der Mei I. Ultraviolet radiation and autoimmune disease: insights from epidemiological research. Toxicology 2002, 181-182:71-78.
141. Embry A.F., Snowdon L.R., Vieth R. VD and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis [letter]. Ann Neurol 2000, 48:271-272.
142. Mahon B.D., Gordon S.A., Cruz J., Cosman F., Cantorna M.T. Cytokine profile in patients with multiple sclerosis following VD supplementation. J Neuroimmunol 2003, 134:128-132.
143. Carrieri P.B., Provitera V., De Rosa T., Tartaglia G., Gorga F., Perrella O. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting sclerosis: a correlation with clinical activity. Immunopharmacol Immunotoxicol 1998, 20:373-382.
144. Losy J., Michalowska-Wender G. In vivo effect of interferon-beta 1a on interleukin-12 and TGF-beta(1) cytokines in patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand 2002, 106:44-46.
145. Lee S., Clark S.A., Gill R.K., Christakos S. 1,25-Dihydroxyvitamin D3 and pancreatic beta-cell function: VDreceptors, gene expression, and insulin secretion. Endocrinology 1994, 134:1602-1610.
146. Mathieu C., Badenhoop K. VD and type 1 diabetes mellitus: state of the art. Trends Endocrinol Metab 2005, 16:261-266.
147. Guenther L., Cambazard F., Van De Kerkhof P.C.M., et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002, 147:316-323.
148. Smith E.L., Walworth N.C., Holick M.F. Effect of 1α,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 1986, 86:709-714.
149. MacLaughlin J.A., Gange W., Taylor D., Smith E., Holick M.F. Cultured psoriatic fibroblasts from involved and uninvolved sites have a partial but not absolute resistance to the proliferation-inhibition activity of 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1985, 82:5409-5412.
150. Bikle D.D. Vitamin D: role in skin and hair. Vitamin D 2005, vol 1:609-630. Elsevier Academic Press, San Diego, Calif. 2nd ed.
151. Smith E.L., Pincus S.H., Donovan L., Holick M.F. A novel approach for the evaluation and treatment of psoriasis: oral or topical use of 1,25-dihydroxyvitamin D3 can be a safe and effective therapy for psoriasis. J Am Acad Dermatol 1988, 19:516-528.
152. Perez A., Chen T.C., Turner A., et al. Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996, 134:238-246.
153. Sanghi D., Mishra A., Sharma A.C., et al. Does vitamin D improve osteoarthritis of knee: a randomized controlled pilot tril. Clin Orthop Relat Res 2013, 471:3556-3562.
154. Castillo E.C., Hernendez-Cueto M.A., Vega-lopez C. Effect of vitamin D supplementation during the induction and progression of osteoarthritis in rat model. Evid Based Complement Alternat Med 2012, 156563.
155. Singh A., Agarwal A.C., Kalia R.B. Vitamin D deficiency and degenerative disc disease in childhood. Orthop J MP 2014, 20:58-60.
156. Colombini A., Cauci S., Lombardi G., et al. Relationship between vitamin D receptor gene(VDR) polymorphism, vitamin d status, osteoarthritis and intervertebral disc degeneration. J Steroid Biochem Mol Biol 2013, 138:24-40.
157. Welsh P., Sattar N. Vitamin D and chronic disease prevention. BMJ 2014, 348:g2280.